Ryan, Christine E. http://orcid.org/0000-0003-2588-1943
Brander, Danielle M.
Barr, Paul M. http://orcid.org/0000-0002-9733-401X
Tyekucheva, Svitlana http://orcid.org/0000-0002-3119-6507
Hackett, Liam R. http://orcid.org/0000-0002-3330-2369
Collins, Mary C.
Fernandes, Stacey M.
Ren, Yue
Zhou, Yinglu http://orcid.org/0000-0001-6276-635X
McDonough, Mikaela M.
Walker, Heather A. http://orcid.org/0000-0002-8015-4071
McEwan, Monica R.
Abramson, Jeremy S.
Jacobsen, Eric D.
LaCasce, Ann S.
Fisher, David C. http://orcid.org/0000-0001-6915-8584
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Davids, Matthew S. http://orcid.org/0000-0003-4529-2003
Funding for this research was provided by:
Genentech
Article History
Received: 6 September 2022
Revised: 16 January 2023
Accepted: 18 January 2023
First Online: 30 January 2023
Competing interests
: CER has received an honorarium from Research to Practice. DMB has served as a consultant for AbbVie, Pharmacyclics, Pfizer, and TG Therapeutics, and has received institutional research funding from AbbVie, ArQule/Merck, Ascentage (transitioning), AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/BMS, MEI Pharma, NeWave, Pharmacyclics, and TG Therapeutics. PMB has received consulting income from Abbvie, Adaptive, AstraZeneca, BeiGene, Celgene/BMS, Genentech, Gilead, Janssen, Merck, Morphosys, TG therapeutics, and Seattle Genetics. JSA has received institutional research support from AbbVie, BeiGene, Bristol-Myers Squibb, Genentech and Seagen, and consulting income from AbbVie, AstraZeneca, Bristol-Myers Squibb, Caribou Biosciences, Century Therapeutics, Epizyme, Genentech, Genmab, Incyte, Janssen, Lilly, MorphoSys, Mustang Bio and Regeneron. ASL has received personal consulting income from Research to Practice. JRB has served as a consultant for Abbvie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Hutchmed, iOnctura, Janssen, Loxo, MEI Pharma, Morphosys AG, Nextcea, Novartis, Pfizer, Pharmacyclics, Rigel; received research funding from BeiGene, Gilead, Loxo/Lilly, MEI Pharma, Sun, Verastem/SecuraBio, and TG Therapeutics; and served on data safety monitoring committees for Invectys and Morphosys. MSD has received institutional research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics and personal consulting income from AbbVie, Adaptive Biosciences, Aptitude Health, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Celgene, Curio Science, Eli Lilly, Genentech, Janssen, Merck, ONO Pharmaceuticals, Research to Practice, TG Therapeutics, and Takeda. ST, LRH, MCC, SMF, YR, YZ, MMM, HAW, MRM, EDJ, and DCF declare no relevant competing interests.